MedTrace Logo

Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma

NCT03356678 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 33

Last updated 2017-11-29

No results posted yet for this study

Summary

A non-interventional, multicenter, multinational retrospective analysis using electronic case report forms completed by the investigators based on information from patient medical records

Conditions

  • Relapsed or Refractory Peripheral T-cell Lymphoma

Interventions

DRUG

Pralatrexate

* Patients treated with pralatrexate due to relapse or refractory disease after primary and/or salvage treatment. Relapse following an autologous stem cell transplant allowed. * Patients treated with pralatrexate 30mg/m2 once a week for 6 weeks as part of a 7-week cycle. However, modified dose and/or schedule allowed.

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-23
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03356678 on ClinicalTrials.gov